« Return to News | CROs/Service Providers

Quintiles Adds Anatomic Pathology Services to China Lab

Tuesday, February 23, 2010 07:49 AM

Quintiles added anatomic pathology to the service offerings it provides at its central laboratory in Beijing, China. The new services complement assay development, digital pathology and core lab offerings, which the Beijing facility already offers to help customers comply with China’s restrictions on tissue import and export.

“Within China, we are providing the tools and infrastructure to investigate cancer and match patients with optimum treatments for their genetic makeup,” said Christopher Ung, Quintiles’ vice president of strategic business and operations, oncology. “These capabilities enable personalized medicine and enhance oncology research to bring medicines to market faster.”

The Beijing anatomic pathology lab also received College of American Pathologists (CAP) accreditation. The central lab at the Beijing site already was CAP-accredited. Quintiles has nine accredited labs—one each in Argentina, Brazil, China, India, Japan, Singapore, Scotland, South Africa and the U.S.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.